Phase 3 Data on solanezumab for Preclinical Alzheimer's.

Published Date: 22 Jul 2023

According to the findings of a phase 3 trial, solanezumab, a monoclonal antibody that binds to the soluble or monomeric form of amyloid-beta, is not any more effective than a placebo at slowing the progression of preclinical Alzheimer's.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Common intracellular toxin could help fight leukemia

2.

CAR T-Cell Therapy Shows Promise in Mantle Cell Lymphoma

3.

Scholastic performance is a key concern for young cancer patients, study finds

4.

AACR: American Association for Cancer Research

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot